Xinlitai announced that the company recently received the “Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing to carry out clinical trials of the innovative siRNA drug Sal0195 injection independently developed by the company to treat increased lipoprotein. SAL0195 has a long-term effect of target knockout in a preclinical monkey model that lasts 140 days with a single dose.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.